申请人:Zeneca Limited
公开号:US05714496A1
公开(公告)日:1998-02-03
Compounds of formula (I) and their pharmaceutically acceptable salts in which R.sup.1 is hydrogen or hydroxy; R.sup.2 is hydrogen; or R.sup.1 and R.sup.2 are joined together so that CR.sup.1 -CR.sup.2 is a double bond; X is selected from --CH.sub.2 CH.sub.2 --, --CH.dbd.CH--, --C.tbd.C--, --CH.sub.2 O--, --CH.sub.2 NH--, --NHCH.sub.2 --, --CH.sub.2 CO--, --COCH.sub.2 --, --CH.sub.2 S-- and --SCH.sub.2 --; Ar.sup.1 is a phenylene moiety; Ar.sup.2 is a heteroaryl moiety; and wherein one or both of Ar.sup.1 and Ar.sup.2 may optionally bear one or more substituents independently selected from halogeno, hydroxy, amino, nitro, cyano, carboxy, carbamoyl, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, di-alkylamino, N-alkylcarbamoyl, di-N,N-alkylcarbamoyl, alkoxycarbonyl, alkylthio, alkylsulphinyl, alkylsulphonyl, halogeno-alkyl, carboxyalkyl and alkanoylamino; provided that when R.sup.1 is hydroxy, X is not selected from --NHCH.sub.2 -- and --SCH.sub.2 --; are inhibitors of squalene synthase and hence useful in treating medical conditions in which a lowering of cholesterol is beneficial, such as hypercholesterolemia and atherosclerosis. Processes for preparing these derivatives, pharmaceutical compositions containing them are also described together with their use in medicine.
化合物的化学式(I)及其药用盐,其中R.sup.1为氢或羟基;R.sup.2为氢;或R.sup.1和R.sup.2结合在一起,使得CR.sup.1 -CR.sup.2为双键;X从--CH.sub.2 CH.sub.2 --,--CH.dbd.CH--,--C.tbd.C--,--CH.sub.2 O--,--CH.sub.2 NH--,--NHCH.sub.2 --,--CH.sub.2 CO--,--COCH.sub.2 --,--CH.sub.2 S--和--SCH.sub.2 --中选择;Ar.sup.1为苯基;Ar.sup.2为杂环芳基;其中Ar.sup.1和Ar.sup.2中的一个或两个可以选择性地带有一个或多个取代基,取代基独立地从卤素,羟基,氨基,硝基,氰基,羧基,氨基甲酰基,烷基,烯基,炔基,烷氧基,烷基氨基,二烷基氨基,N-烷基氨基甲酰基,二N,N-烷基氨基甲酰基,烷氧羰基,烷基硫醚,烷基砜基,卤代烷基,羧基烷基和烷酰胺基中独立选择;但当R.sup.1为羟基时,X不可从--NHCH.sub.2 --和--SCH.sub.2 --中选择;是皂化酶的抑制剂,因此在治疗降低胆固醇有益的医疗状况中有用,如高胆固醇血症和动脉粥样硬化。还描述了制备这些衍生物的方法,含有它们的药物组合物以及它们在医学中的用途。